Raya Therapeutic Announces Supportive Clinical Results of Fasudil (RT1968) in ALS Patients

MONTREAL, June 17, 2024 /PRNewswire/ — Raya Therapeutic Inc., (“Raya”) a mission-driven company focused on the treatment of ALS and other neurodegenerative diseases, is pleased to announce supportive clinical data for its lead compound, fasudil (RT1968, in the treatment of Amyotrophic…